Abstract
Capsaicin has significant promise as a non-opioid analgesic due to its ability to selectively desensitize pain fibers for weeks to months after a single administration. A highly purified formulation of capsaicin (Adlea™, Anesiva, Inc.) is under development for both intraoperative instillation into open surgical wounds and local injection into anatomical sites of pain. Phase 1 and 2 trials of this novel formulation suggest efficacy and safety in a variety of surgical and nonsurgical settings. ACTIVE-2 is a phase 3 study designed to evaluate the efficacy and safety of the capsaicin formulation for management of postoperative pain from total knee arthroplasty (TKA).
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call